JOP20220251A1 - تركيبات صيدلانية سائلة من عقاقير أولية أساسها متعدد إثيلين غليكول من أدرينوميدولين واستخدامها - Google Patents

تركيبات صيدلانية سائلة من عقاقير أولية أساسها متعدد إثيلين غليكول من أدرينوميدولين واستخدامها

Info

Publication number
JOP20220251A1
JOP20220251A1 JOP/2022/0251A JOP20220251A JOP20220251A1 JO P20220251 A1 JOP20220251 A1 JO P20220251A1 JO P20220251 A JOP20220251 A JO P20220251A JO P20220251 A1 JOP20220251 A1 JO P20220251A1
Authority
JO
Jordan
Prior art keywords
adrenomedullin
polyethylene glycol
pharmaceutical formulations
liquid pharmaceutical
based prodrugs
Prior art date
Application number
JOP/2022/0251A
Other languages
English (en)
Inventor
Christian Schneid Stefan
Unger Florian
Haasbach Carina
Motzkus Hans-Walter
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Priority claimed from PCT/EP2021/058427 external-priority patent/WO2021198327A1/en
Publication of JOP20220251A1 publication Critical patent/JOP20220251A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبات صيدلانية سائلة جديدة، يفضل أن تكون معدّة للاستنشاق، تشتمل على عقاقير أولية أساسها متعدد إثيلين غليكول (PEG) من الأدرينوميدولين (PEG-ADM) واستخدامها لمعالجة و/أو الوقاية من إصابة الرئة الحادة /متلازمة الضائقة التنفسية الحادة (ALI/ARDS)
JOP/2022/0251A 2020-04-03 2021-03-31 تركيبات صيدلانية سائلة من عقاقير أولية أساسها متعدد إثيلين غليكول من أدرينوميدولين واستخدامها JOP20220251A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20168075 2020-04-03
PCT/EP2021/058427 WO2021198327A1 (en) 2020-04-03 2021-03-31 Liquid pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use

Publications (1)

Publication Number Publication Date
JOP20220251A1 true JOP20220251A1 (ar) 2023-01-30

Family

ID=70189768

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0251A JOP20220251A1 (ar) 2020-04-03 2021-03-31 تركيبات صيدلانية سائلة من عقاقير أولية أساسها متعدد إثيلين غليكول من أدرينوميدولين واستخدامها

Country Status (18)

Country Link
US (1) US20230364245A1 (ar)
EP (1) EP4126061A1 (ar)
JP (1) JP2023520543A (ar)
KR (1) KR20220163413A (ar)
CN (1) CN115666654A (ar)
AU (1) AU2021247501A1 (ar)
BR (1) BR112022017588A2 (ar)
CA (1) CA3177217A1 (ar)
CL (1) CL2022002639A1 (ar)
CO (1) CO2022014154A2 (ar)
CR (1) CR20220500A (ar)
DO (1) DOP2022000212A (ar)
EC (1) ECSP22077374A (ar)
IL (1) IL297014A (ar)
JO (1) JOP20220251A1 (ar)
MX (1) MX2022012318A (ar)
PE (1) PE20231070A1 (ar)
WO (1) WO2021198328A1 (ar)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6085740A (en) 1996-02-21 2000-07-11 Aerogen, Inc. Liquid dispensing apparatus and methods
US6235177B1 (en) 1999-09-09 2001-05-22 Aerogen, Inc. Method for the construction of an aperture plate for dispensing liquid droplets
WO2003059424A1 (en) 2002-01-15 2003-07-24 Aerogen, Inc. Methods and systems for operating an aerosol generator
JOP20190001B1 (ar) 2011-11-03 2022-03-14 Bayer Pharma AG عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه

Also Published As

Publication number Publication date
ECSP22077374A (es) 2022-11-30
CO2022014154A2 (es) 2022-10-31
CR20220500A (es) 2022-11-18
WO2021198328A1 (en) 2021-10-07
KR20220163413A (ko) 2022-12-09
PE20231070A1 (es) 2023-07-17
MX2022012318A (es) 2022-10-27
DOP2022000212A (es) 2022-10-31
US20230364245A1 (en) 2023-11-16
CL2022002639A1 (es) 2023-04-10
EP4126061A1 (en) 2023-02-08
CA3177217A1 (en) 2021-10-07
BR112022017588A2 (pt) 2022-10-18
IL297014A (en) 2022-12-01
AU2021247501A1 (en) 2022-10-27
CN115666654A (zh) 2023-01-31
JP2023520543A (ja) 2023-05-17

Similar Documents

Publication Publication Date Title
MX2021004692A (es) Composicion y metodo para tratar pulmones.
CY1125329T1 (el) Αντιιικες ενωσεις πυραζολο- και τριαζολο-πυριμιδινης εναντι toy rsv
MX2023006541A (es) Formulaciones de dosis fija.
MX2016012766A (es) Sistema y metodo para suministro de gas terapeutico a pacientes en necesidad del mismo usando la medicion de flujo de gas de circuito de respiracion (bcg) mejorada.
MX2020011872A (es) Sistemas y método para suministro de gas terapéutico a pacientes, en necesidad del mismo, que reciben gas de respiración desde un ventilador que varía por lo menos en presión y/o flujo usando la medición de flujo de gas terapéutico (no) mejorada.
TN2014000185A1 (en) Polyethylene glycol based prodrug of adrenomedullin and use thereof
PH12017502087B1 (en) Tiotropium inhalation solution for nebulization
MX2018009870A (es) Inhibidores de taf1 para la terapia del cancer.
EA201892327A1 (ru) Ингаляционные и назальные бензодиазепины
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
WO2014007772A3 (en) Inhalation compositions comprising glucose anhydrous
WO2014007781A3 (en) Inhalation compositions
MX2021004860A (es) Piridazinas novedosas.
UA118192C2 (uk) Противірусна фармацевтична композиція
GB201205739D0 (en) Treatment of acute inflammation in the respiratory tract
MX2020010738A (es) Formulaciones de ciclosporina para uso en el tratamiento del sindrome de bronquiolitis obliterante (bos).
CR20220499A (es) Formulaciones farmacéuticas líquidas de profármacos a base de polietilenglicol de adrenomedulina y su uso
JOP20220251A1 (ar) تركيبات صيدلانية سائلة من عقاقير أولية أساسها متعدد إثيلين غليكول من أدرينوميدولين واستخدامها
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
MX2018002075A (es) Composicion que comprende taninos.
PH12020500022A1 (en) Salt of (ss)-adenosyl methionine with inositol hexaphosphate, and process for the preparation thereof
IN2014MN02133A (ar)
EP4335460A3 (en) Compositions and methods for treating granulomatosis with polyangiitis
MX2014001940A (es) Producto farmaceutico de aerosol para administracion por inhalacion oral o nasal.
TH175724B (th) อนุภาคเมลาโทนิน (melatonin vesicles) สำหรับใช้ทางจมูก